MM-121 + Paclitaxel

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

Conditions

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Trial Timeline

Oct 1, 2010 → Jul 1, 2014

NCT ID

NCT01209195

About MM-121 + Paclitaxel

MM-121 + Paclitaxel is a phase 1 stage product being developed by Sanofi for Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,. The current trial status is completed. This product is registered under clinical trial identifier NCT01209195. Target conditions include Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01447706	Phase 2	Completed	Oct 1, 2011	Jun 1, 2015	Epithelial Ovarian Cancer
NCT01421472	Phase 2	Completed	Aug 1, 2011	Jun 1, 2014	ER Positive, Her2 Negative Breast Cancer Patients
NCT01209195	Phase 1	Completed	Oct 1, 2010	Jul 1, 2014	Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

Competing Products

20 competing products in Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
NBTXR3	Nanobiotix	Phase 1/2	36
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
zolbetuximab	Astellas Pharma	Pre-clinical	23
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	77
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	23
zolbetuximab	Astellas Pharma	Pre-clinical	23
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	77
ASP3082	Astellas Pharma	Phase 2	52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	77
ASP1948	Astellas Pharma	Phase 1	33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	52

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved